dalteparin has been researched along with thiophenes in 114 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 32 (28.07) | 29.6817 |
| 2010's | 82 (71.93) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bauer, KA; Fisher, WD; Gent, M; Irwin, MW; Kälebo, P; Kwong, LM; Misselwitz, F; Turpie, AG | 1 |
| Borris, L; Dahl, OE; Eriksson, BI; Haas, S; Huisman, MV; Kakkar, AK; Kälebo, P; Misselwitz, F | 1 |
| Biemond, BJ; Buetehorn, U; Büller, HR; Friederich, PW; Levi, M; Perzborn, E | 1 |
| Beyer, J; Eriksson, BI; Halbritter, K; Kakkar, AK; Kälebo, P; Misselwitz, F; Schellong, SM; Turpie, AG | 1 |
| Ma, Q | 1 |
| Bauer, KA; Borris, L; Dahl, OE; Eriksson, BI; Fisher, WD; Gent, M; Haas, S; Homering, M; Huisman, MV; Kakkar, AK; Kälebo, P; Kwong, LM; Misselwitz, F; Turpie, AG | 1 |
| Kubitza, D; Laux, V; Misselwitz, F; Perzborn, E | 1 |
| Bandel, TJ; Beckmann, H; Borris, LC; Eriksson, BI; Friedman, RJ; Geerts, W; Haas, S; Huisman, MV; Kakkar, AK; Misselwitz, F; Muehlhofer, E | 1 |
| Ageno, W; Bandel, TJ; Borris, LC; Lassen, MR; Lieberman, JR; Misselwitz, F; Rosencher, N; Turpie, AG | 1 |
| Becker, RC; Lohrmann, J | 1 |
| Brenner, B; Dahl, OE; Eriksson, BI; Haas, S; Kakkar, AK; Misselwitz, F; Mouret, P; Muntz, J; Pap, AF; Soglian, AG | 1 |
| Eikelboom, JW; Weitz, JI | 1 |
| Bakhos, M; Hoppensteadt, D; Iqbal, O; Jeske, WP; Maddineni, J; Messmore, HL; Prechel, M; Walenga, JM | 1 |
| Connolly, ES; Komotar, RJ; Starke, RM | 1 |
| Schuman, EP | 1 |
| Lotke, PA | 1 |
| Hamulyak, K; ten Cate, H | 1 |
| Francis, CW | 1 |
| Garcia Nuño, L; Granero Xiberta, J; Soler Minoves, JM | 1 |
| Arnaout, L; Bellamy, L; Chabbouh, T; Rosencher, N | 1 |
| Albaladejo, P | 1 |
| Harenberg, J; Nitschmann, S | 1 |
| Bandel, TJ; Eriksson, BI; Gent, M; Homering, M; Kakkar, AK; Lassen, MR; Misselwitz, F; Turpie, AG | 1 |
| Bandel, TJ; Bauer, KA; Benson, A; Berkowitz, SD; Cushner, FD; Davidson, BL; Fisher, WD; Gent, M; Kwong, LM; Lassen, MR; Lotke, PA; Misselwitz, F; Turpie, AG | 1 |
| Becker, RC | 1 |
| Eberli, FR; Roffi, M | 1 |
| Stief, T | 1 |
| Denaro, V; Longo, UG; Maffulli, N | 1 |
| Dimmitt, S; Eikelboom, JW; Raju, NC | 1 |
| Blázquez-Pérez, A; Gómez-Outes, A; Pozo-Hernández, C; Suárez-Gea, ML; Vargas-Castrillón, E | 1 |
| Barry, M; McCullagh, L; Tilson, L; Walsh, C | 1 |
| Verma, AK | 1 |
| Dick, W; Saxer, F | 1 |
| Kolundzic, R; Trkulja, V | 1 |
| Aïssaoui, N; Danchin, N | 1 |
| Ananthapavan, J; Diamantopoulos, A; Forster, F; Lees, M; McDonald, H; Wells, PS | 1 |
| Cao, YB; Jiang, YY; Shen, H; Zhang, JD | 1 |
| Clemens, A; Monz, BU; Plumb, JM | 1 |
| Dahl, OE; Huisman, MV; Quinlan, DJ; Schulman, S | 1 |
| Burton, P; Gheorghiade, M; Greenberg, BH; Mehra, M; Nadar, VK; Plotnikov, AN; Sun, X; Thyssen, A; Tian, H; Zolynas, R | 1 |
| Chitolie, A; Green, L; Haddad, FS; Hossain, F; Lawrie, AS; Machin, SJ; Mackie, IJ; Patel, S | 1 |
| Agnelli, G; Bauersachs, R; Berkowitz, SD; Bounameaux, H; Brenner, B; Buller, HR; Cohen, A; Davidson, BL; Decousus, H; Gallus, AS; Lensing, AW; Misselwitz, F; Piovella, F; Prins, MH; Raskob, GE; Schellong, S; Segers, A; Verhamme, P; Wells, P | 1 |
| Bandel, TJ; Berkowitz, SD; Eriksson, BI; Gent, M; Homering, M; Kakkar, AK; Lassen, MR; Misselwitz, F; Turpie, AG; Westermeier, T | 1 |
| Hylek, EM | 1 |
| Jensen, CD; Muller, SD; Partington, PF; Reed, MR; Steval, A | 1 |
| Kwok, CS; Loke, YK | 1 |
| Berkowitz, SD; Desai, M; Horsmans, Y; Larrey, D; Maddrey, W; Peters, G; Watkins, PB | 1 |
| Diamantopoulos, A; Lees, M; Lereun, C; Rasul, F; Sengupta, N; Wells, P | 1 |
| Banghua, L; Jin, C; Turun, S; Ying, N; Yuan, Y; Zhenhui, L | 1 |
| Gans, RO; Landman, GW | 1 |
| Kwong, LM | 1 |
| Burghaus, R; Coboeken, K; Gaub, T; Kuepfer, L; Lippert, J; Mueck, W; Sensse, A; Siegmund, HU; Weiss, W | 1 |
| Merli, G | 1 |
| Delbeck, M; Ellinghaus, P; Kast, R; Laux, V; Nickel, KF; Perzborn, E; Schäfer, S; Schermuly, RT; Strassburger, J; von Degenfeld, G | 1 |
| Fadda, V; Maratea, D; Messori, A; Trippoli, S | 1 |
| Carballo, D; Carballo, S; Keller, PF; Roffi, M | 1 |
| Friedman, RJ | 1 |
| Blombery, PA | 1 |
| Andrade-Gordon, P; Chen, C; Connelly, MA; Damiano, BP; Huang, Z; Parry, TJ; Perzborn, E | 1 |
| Diamantopoulos, A; Duran, A; Forster, F; Kwong, L; Lees, M; Sengupta, N | 2 |
| Mulhall, KJ; Solayar, GN; Walsh, PM | 1 |
| Dahl, OE; Eriksson, BI; Friedman, RJ; Homering, M; Rosencher, N | 1 |
| Migliaccio-Walle, K; Rublee, D; Simon, TA | 1 |
| Espada, NG; González, TC; Merino, RG; Nieto, JA | 1 |
| Agnelli, G; Berkowitz, SD; Bounameaux, H; Büller, HR; Chlumsky, J; Cohen, A; Davidson, BL; Decousus, H; Gallus, AS; Jacobson, BF; Lensin, AW; Minar, E; Misselwitz, F; Prins, MH; Raskob, GE; Schellong, S; Segers, A; Verhamme, P; Wells, P | 1 |
| Barry, M; McCullagh, L; Walsh, C | 1 |
| Gómez-Outes, A; Suárez-Gea, ML; Terleira-Fernández, AI; Vargas-Castrillón, E | 1 |
| Müller, D; Stock, S; Stollenwerk, B; Zindel, S | 1 |
| Dahl, OE; Harenberg, J; Marder, VJ; Marx, S; Schulze, A; Wehling, M; Weiss, C | 1 |
| Berkowitz, SD; Eriksson, BI; Gent, M; Homering, M; Kakkar, AK; Lassen, MR; Turpie, AG | 1 |
| Hannan, T; Khalafallah, AA; Renu, S; Sharp, C | 1 |
| Coste, P; Gerbaud, E; Seguy, B | 1 |
| Betegón Nicolás, L; de Salas-Cansado, M; Gómez Arrayas, I; Gómez Cerezo, JF; Rubio-Terrés, C; Suárez Fernández, C | 1 |
| Berkowitz, SD; Homering, M; Llau, JV; Loewe, A; Mueck, W; Rosencher, N | 1 |
| Büller, HR; Cohen, AT; Haskell, L; Hu, D; Hull, R; Mebazaa, A; Merli, G; Schellong, S; Spiro, TE; Spyropoulos, AC; Tapson, V | 1 |
| Jeer, P; Rose, B; Saran, D; Shrivastava, R; Sindali, K; Soueid, H | 1 |
| Abe, K; Conley, PB; DeGuzman, FR; Hollenbach, SJ; Hutchaleelaha, A; Inagaki, M; Karbarz, MJ; Lee, G; Lu, G; Luan, P; Phillips, DR; Sinha, U | 1 |
| Kwok, CS; Loke, YK; Pradhan, S; Yeong, JK | 1 |
| Cohen, AT; Spiro, TE; Spyropoulos, AC | 1 |
| Alameddine, R; Husari, A | 1 |
| Derksen, RJ; Mulder, JW; Mulder, WM | 1 |
| Sohne, M; Vink, R | 1 |
| Klein, HH | 1 |
| Jing, J; Li, J; Zhan, J; Zhou, Y | 1 |
| Bamber, L; Bauersachs, R; Cano, SJ; Ciniglio, C; Lensing, AW; Prins, MH; Wang, MY | 1 |
| Díaz de Rada, P; González, AB; Muñoa, L; Valentí, A; Valentí, JR | 1 |
| Alabalik, U; Azboy, I; Bulut, M; Demirtas, A; Necmioglu, NS; Ucar, BY | 1 |
| Accassat, S; Bertoletti, L; Décousus, H; Lega, JC; Merah, A; Mismetti, P | 1 |
| Cohen, AA; Rider, T | 1 |
| Brosa, M; Diamantopoulos, A; Folkerts, K; Imberti, D; Monreal, M | 1 |
| Dugdale, M; Fabian, TC; Gordon, JL; Lee, MD | 1 |
| Haas, S; Holberg, G; Jamal, W; Kreutz, R; Lassen, MR; Mantovani, LG; Pattanayak, CW; Schmidt, A; Turpie, AG; van Eickels, M | 1 |
| Bookhart, BK; Coleman, CI; Huynh, L; Lefebvre, P; Mody, SH; Nutescu, EA; Tran, KN; Wang, ST; Zhuo, DY | 1 |
| Caliskan, A; Demirtas, S; Guclu, O; Karahan, O; Mavitas, B; Yavuz, C; Yazici, S | 1 |
| Bamber, L; Correa de Carvalho, F; Lensing, AW; Prins, M; van Bellen, B; Wang, M | 1 |
| Büller, HR; Burton, P; Cohen, AT; Desanctis, YH; Haskell, L; Homering, M; Hu, D; Hull, R; Mebazaa, A; Merli, G; Schellong, S; Spiro, TE; Spyropoulos, AC; Tapson, VF | 1 |
| Gupta, K; Singh, D; Vacek, JL | 1 |
| Jing, J; Li, J; Yao, Y; Zhan, J; Zhou, Y | 1 |
| Berkowitz, SD; Berlin, JA; DiBattiste, PM; Friedman, RJ; Homering, M; Levitan, B; Turpie, AG; Weinstein, RB; Yuan, Z | 1 |
| Brighton, TA; Davidson, BL; Gebel, M; Lensing, AW; Lyons, RM; Prins, MH; Rehm, J; Verheijen, S | 1 |
| Alabalik, U; Alemdar, C; Azboy, I; Bulut, M; Demirtaş, A; Uçar, Y | 1 |
| Lip, GY; Shantsila, E | 1 |
| Büller, HR; Cohen, AT; De Sanctis, Y; Haskell, L; Hu, D; Hull, R; Mebazaa, A; Merli, G; Schellong, SW; Spiro, TE; Spyropoulos, AC; Tapson, VF | 1 |
| Ay, C; Hayde, M; Königsbrügge, O; Langer, M; Pabinger, I | 1 |
| Bamber, L; Bookhart, BK; Haskell, L; Mody, SH; Schein, J; Wang, M | 1 |
| Auckenthaler, T; Innerhofer, P; Oswald, E; Streif, W; Tauber, H; Ulmer, H; Velik-Salchner, C | 1 |
| Anderson, JL; Bates, ER; Bode, C; Granger, CB; Huber, K; Kristensen, SD; Lopez Sendon, JL; Ohman, EM; Steg, PG; Tubaro, M; Valgimigli, M; Wallentin, L | 1 |
| Feuerstein, JD; Ketwaroo, GA; Leffler, DA; Patwardhan, VR; Sengupta, N; Tapper, EB; Thaker, AM | 1 |
| Cohen, AT; Lensing, AW; Müller, K; Pap, ÁF; Prandoni, P; Prins, MH; Tewes, MC | 1 |
| Bakchoul, T; Ganzel, C; Greinacher, A; Rowe, JM; Tvito, A | 1 |
| Calıskan, A; Demirtas, S; Guclu, O; Kaplan, I; Karahan, O; Tezcan, O; Yavuz, C; Yazıcı, S | 1 |
| Gage, BF; Ganti, BR; Lee, ED; Lin, H; Nunley, RM; Venker, BT | 1 |
| Beyer-Westendorf, J | 1 |
23 review(s) available for dalteparin and thiophenes
| Article | Year |
|---|---|
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dose-Response Relationship, Drug; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Humans; Incidence; Male; Middle Aged; Morpholines; Phlebography; Pulmonary Embolism; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thrombosis | 2007 |
Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.
Topics: Administration, Oral; Animals; Anticoagulants; Bleeding Time; Clinical Trials, Phase II as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Orthopedics; Rivaroxaban; Thiophenes; Thromboembolism | 2007 |
[Rivaroxaban (Xarelto): efficacy and safety].
Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Agents; Hematoma, Epidural, Spinal; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Morpholines; Postoperative Complications; Preanesthetic Medication; Rivaroxaban; Thiophenes; Thromboembolism | 2008 |
Diabetes and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Blood Glucose; Clopidogrel; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Enoxaparin; Hirudins; Humans; Hypoglycemic Agents; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Thiophenes; Thrombosis; Ticlopidine | 2009 |
Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Enoxaparin; Hemorrhage; Humans; Morpholines; Postoperative Care; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Safety; Survival Analysis; Thiophenes; Venous Thromboembolism | 2010 |
Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Disease Management; Drug Synergism; Drug Therapy, Combination; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Canada; Cost-Benefit Analysis; Enoxaparin; Follow-Up Studies; Humans; Morpholines; Postoperative Complications; Quality of Life; Rivaroxaban; Sensitivity and Specificity; Thiophenes; Venous Thromboembolism | 2010 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Double-Blind Method; Enoxaparin; Hemorrhage; Humans; Incidence; Morpholines; Multicenter Studies as Topic; Odds Ratio; Primary Prevention; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2010 |
Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2011 |
A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Female; Humans; Male; Middle Aged; Morpholines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism; Young Adult | 2011 |
Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cost-Benefit Analysis; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; United States; Venous Thromboembolism | 2011 |
Prevention of venous thromboembolism after major orthopedic surgery: indirect comparison of three new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Morpholines; Orthopedic Procedures; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2011 |
Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Endpoint Determination; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Relative effects of two different enoxaparin regimens as comparators against newer oral anticoagulants: meta-analysis and adjusted indirect comparison.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
[Electrical cardioversion for non-valvular atrial fibrillation--underestimated risk for thromboembolic complications?].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Electric Countershock; Enoxaparin; Heparin; Humans; International Normalized Ratio; Morpholines; Phenprocoumon; Practice Guidelines as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
Rivaroxaban is as efficient and safe as bemiparin as thromboprophylaxis in knee arthroscopy.
Topics: Adult; Aged; Arthroscopy; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Follow-Up Studies; Heparin, Low-Molecular-Weight; Humans; Knee Joint; Male; Middle Aged; Morpholines; Polypharmacy; Postoperative Complications; Postoperative Hemorrhage; Retrospective Studies; Risk Factors; Rivaroxaban; Therapeutic Equipoise; Thiophenes; Thrombophilia; Venous Thrombosis | 2014 |
NOACs for thromboprophylaxis in medical patients.
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Enoxaparin; Humans; Morpholines; Postoperative Hemorrhage; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies.
Topics: Anticoagulants; Aspirin; Benzimidazoles; Clopidogrel; Dabigatran; Emergencies; Enoxaparin; Fondaparinux; Heparin; Humans; Morpholines; Platelet Aggregation Inhibitors; Platelet Transfusion; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Ticlopidine; Warfarin | 2013 |
Anticoagulation and antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Enoxaparin; Fondaparinux; Heparin; Hirudins; Humans; Morpholines; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2014 |
Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Fondaparinux; Heparin; Hirudins; Humans; Lactones; Peptide Fragments; Peptides; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Recombinant Proteins; Thiophenes; Ticagrelor; Tirofiban; Tyrosine; Warfarin | 2014 |
Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Dabigatran; Enoxaparin; Fondaparinux; Hemorrhage; Humans; Morpholines; Polysaccharides; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2017 |
26 trial(s) available for dalteparin and thiophenes
| Article | Year |
|---|---|
BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombin III; Arthroplasty, Replacement, Knee; Double-Blind Method; Enoxaparin; Hemorrhage; Humans; Incidence; Injections, Subcutaneous; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism; Venous Thrombosis | 2005 |
Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Dose-Response Relationship, Drug; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Pulmonary Embolism; Rivaroxaban; Thiophenes; Thromboembolism; Venous Thrombosis | 2006 |
Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study.
Topics: Anticoagulants; Enoxaparin; Hip Prosthesis; Humans; Knee Prosthesis; Morpholines; Orthopedic Procedures; Phlebography; Postoperative Complications; Rivaroxaban; Sensitivity and Specificity; Thiophenes; Ultrasonography; Venous Thrombosis | 2007 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2008 |
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2008 |
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism; Young Adult | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method; Enoxaparin; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Morpholines; Phlebography; Risk Reduction Behavior; Rivaroxaban; Sensitivity and Specificity; Thiophenes; Treatment Outcome; Venous Thrombosis | 2009 |
Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Canada; Cost-Benefit Analysis; Enoxaparin; Follow-Up Studies; Humans; Morpholines; Postoperative Complications; Quality of Life; Rivaroxaban; Sensitivity and Specificity; Thiophenes; Venous Thromboembolism | 2010 |
Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Follow-Up Studies; Hemorrhage; Humans; Morpholines; Postoperative Complications; Prospective Studies; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism; Withholding Treatment | 2010 |
Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombin III; Biomarkers; Chronic Disease; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Female; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Heart Failure; Humans; Male; Middle Aged; Morpholines; Peptide Fragments; Peptide Hydrolases; Prothrombin; Rivaroxaban; Thiophenes; Thrombophilia | 2011 |
The impact of elective knee/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dalteparin; Factor Xa; Female; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Prospective Studies; Rivaroxaban; Thiophenes; Thrombin; Treatment Outcome; Venous Thromboembolism | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Injections, Subcutaneous; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Vitamin K; Warfarin | 2010 |
Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Alanine Transaminase; Alkaline Phosphatase; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Bilirubin; Chemical and Drug Induced Liver Injury; Double-Blind Method; Enoxaparin; Female; Fibrinolytic Agents; Humans; Liver Function Tests; Male; Middle Aged; Morpholines; Rivaroxaban; Severity of Illness Index; Thiophenes | 2011 |
Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Drug Interactions; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Platelet Aggregation Inhibitors; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up Studies; Hemorrhage; Humans; International Normalized Ratio; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Pulmonary Embolism; Recurrence; Rivaroxaban; Thiophenes; Treatment Outcome; Vitamin K | 2012 |
Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin).
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Female; Hematoma; Humans; Incidence; Male; Middle Aged; Morpholines; Postoperative Complications; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Injections, Subcutaneous; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Morpholines; Patient Satisfaction; Rivaroxaban; Thiophenes; Venous Thrombosis | 2013 |
Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Cost of Illness; Cost-Benefit Analysis; Dabigatran; Direct Service Costs; Enoxaparin; France; Humans; Italy; Models, Theoretical; Morpholines; Postoperative Complications; Pyridines; Quality of Life; Rivaroxaban; Spain; Thiophenes; Venous Thromboembolism | 2013 |
A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment.
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cohort Studies; Data Interpretation, Statistical; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Odds Ratio; Propensity Score; Risk; Rivaroxaban; Standard of Care; Thiophenes; Time Factors; Treatment Outcome; Venous Thromboembolism | 2014 |
Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism.
Topics: Anticoagulants; Enoxaparin; Female; Humans; Length of Stay; Male; Middle Aged; Morpholines; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thrombosis; Vitamin K | 2014 |
D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Enoxaparin; Female; Fibrin Fibrinogen Degradation Products; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Morpholines; Multivariate Analysis; Risk Factors; Rivaroxaban; Thiophenes; Time Factors; Treatment Outcome; Venous Thromboembolism | 2014 |
Predicting the risk of venous thromboembolism in patients hospitalized with heart failure.
Topics: Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Female; Heart Failure; Hemorrhage; Hospitalization; Humans; Incidence; Male; Middle Aged; Morpholines; Multivariate Analysis; Predictive Value of Tests; Primary Prevention; Risk Factors; Rivaroxaban; Severity of Illness Index; Thiophenes; Venous Thromboembolism | 2014 |
Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Safety; Thiophenes; Venous Thromboembolism; Vitamin K | 2015 |
66 other study(ies) available for dalteparin and thiophenes
| Article | Year |
|---|---|
Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
Topics: Administration, Oral; Animals; Anticoagulants; Blood Coagulation Tests; Disease Models, Animal; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Humans; Infusions, Intravenous; Injections, Intravenous; Jugular Veins; Ligation; Morpholines; Nadroparin; Polysaccharides; Rabbits; Random Allocation; Rivaroxaban; Thiophenes; Thromboplastin; Venous Thrombosis | 2007 |
Development of oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Drug Delivery Systems; Drug Design; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Postoperative Hemorrhage; Pyridines; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2007 |
New anticoagulants--the path from discovery to clinical practice.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2008 |
Selective factor Xa inhibition for thromboprophylaxis.
Topics: Anticoagulants; Clinical Trials as Topic; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Postoperative Complications; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2008 |
Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia.
Topics: Analysis of Variance; Anticoagulants; Antithrombin III; Arginine; Autoantibodies; Enoxaparin; Flow Cytometry; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Morpholines; Pipecolic Acids; Platelet Activation; Platelet Aggregation; Platelet Factor 4; Polysaccharides; Rivaroxaban; Sulfonamides; Thiophenes; Thrombocytopenia | 2008 |
Orally administered factor xa inhibitor, rivaroxaban: a novel thromboembolic prophylaxis agent.
Topics: Administration, Oral; Blood Coagulation; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Morpholines; Orthopedic Procedures; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thromboembolism | 2008 |
Rivaroxaban for thromboprophylaxis.
Topics: Anticoagulants; Body Weight; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2008 |
Rivaroxaban for thromboprophylaxis.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pulmonary Embolism; Risk; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2008 |
Rivaroxaban for thromboprophylaxis.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2008 |
New issues in oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clinical Trials as Topic; Cytochrome P-450 CYP2C9; Dabigatran; Enoxaparin; Genetic Variation; Humans; Mixed Function Oxygenases; Morpholines; Pharmacogenetics; Polymorphism, Genetic; Pyridines; Rivaroxaban; Thiophenes; Vitamin K Epoxide Reductases; Warfarin | 2008 |
[Thromboembolic disease in orthopedic surgery].
Topics: Anesthesia, Conduction; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Early Ambulation; Enoxaparin; Fibrinolytic Agents; Hip Fractures; Humans; Intraoperative Care; Morpholines; Orthopedics; Postoperative Care; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Thiophenes; Time Factors; Venous Thromboembolism | 2008 |
[Summary and perspectives. Rivaroxaban].
Topics: Administration, Oral; Aged; Anticoagulants; Clinical Trials, Phase III as Topic; Comorbidity; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Kidney Failure, Chronic; Morpholines; Obesity; Postoperative Complications; Preanesthetic Medication; Rivaroxaban; Thiophenes; Thromboembolism; Thrombophilia; Venous Thrombosis | 2008 |
[New agents for the prevention of venous thromboembolism].
Topics: Benzimidazoles; Dabigatran; Enoxaparin; Fibrinolytic Agents; Humans; Morpholines; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2009 |
The importance of VTE prevention after orthopaedic surgery.
Topics: Anticoagulants; Cost of Illness; Enoxaparin; Evidence-Based Medicine; Humans; Length of Stay; Morpholines; Orthopedic Procedures; Risk Reduction Behavior; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2009 |
Rivaroxaban versus enoxaparin after total knee arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Drug Administration Schedule; Enoxaparin; Humans; Morpholines; Research Design; Rivaroxaban; Thiophenes; Venous Thrombosis | 2009 |
Rivaroxaban versus enoxaparin after total knee arthroplasty.
Topics: Aftercare; Anticoagulants; Arthroplasty, Replacement, Knee; Drug Monitoring; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Patient Selection; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism | 2009 |
Rivaroxaban versus enoxaparin after total knee arthroplasty.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Knee; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Enoxaparin; Europe; Humans; Morpholines; North America; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thrombosis | 2009 |
Rivaroxaban versus enoxaparin after total knee arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrhage; Humans; Morpholines; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Rivaroxaban; Safety; Thiophenes; Venous Thrombosis | 2009 |
A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Decision Trees; Enoxaparin; Fibrinolytic Agents; Humans; Ireland; Models, Economic; Monte Carlo Method; Morpholines; Pyridines; Quality-Adjusted Life Years; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2009 |
New agents for orthopaedic thromboprophylaxis: caution essential, but time will tell.
Topics: Anticoagulants; Benzimidazoles; Dabigatran; Enoxaparin; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pyridines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2009 |
[Prophylaxis of venous thromboembolism in orthopaedic surgery--trivial option, huge potential].
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Coagulation Tests; Combined Modality Therapy; Drug Approval; Drug Interactions; Early Ambulation; Enoxaparin; Factor Xa Inhibitors; Humans; Intermittent Pneumatic Compression Devices; Morpholines; Orthopedic Procedures; Postoperative Care; Postoperative Complications; Practice Guidelines as Topic; Rivaroxaban; Stockings, Compression; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2010 |
Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Clinical Trials as Topic; Cost-Benefit Analysis; Dabigatran; Enoxaparin; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Models, Economic; Morpholines; Polysaccharides; Postoperative Complications; Pyridines; Quality-Adjusted Life Years; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2010 |
Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Clinical Trials, Phase III as Topic; Double-Blind Method; Enoxaparin; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2011 |
Therapeutic potential of oral factor Xa inhibitors.
Topics: Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2010 |
Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Hip Prosthesis; Humans; Knee Prosthesis; Male; Middle Aged; Morpholines; Postoperative Care; Postoperative Complications; Prosthesis-Related Infections; Reoperation; Retrospective Studies; Rivaroxaban; Thiophenes; Thromboembolism; Tinzaparin | 2011 |
An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Female; Health Care Costs; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Risk; Risk Factors; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Morpholines; Pulmonary Embolism; Recurrence; Risk Assessment; Rivaroxaban; Thiophenes; Venous Thrombosis | 2011 |
Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation.
Topics: Anticoagulants; Azetidines; Benzylamines; Blood Circulation; Blood Coagulation; Computer Simulation; Enoxaparin; Humans; Models, Biological; Morpholines; Naphthalenes; Partial Thromboplastin Time; Propionates; Rivaroxaban; Thiophenes; Translational Research, Biomedical; Treatment Outcome; Warfarin | 2011 |
Venous thromboembolism after total hip arthroplasty and total knee arthroplasty: current and future perspectives. Epilogue.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Health Care Costs; Humans; Morpholines; Rivaroxaban; Thiophenes; United States; Venous Thromboembolism | 2011 |
A role for coagulation factor Xa in experimental pulmonary arterial hypertension.
Topics: Animals; Blood Coagulation; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Familial Primary Pulmonary Hypertension; Hemodynamics; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Monocrotaline; Morpholines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Rivaroxaban; Thiophenes; Thrombosis; Warfarin | 2011 |
[Specificities of diabetes in acute coronary syndromes].
Topics: Acute Coronary Syndrome; Algorithms; Angioplasty; Anti-Inflammatory Agents, Non-Steroidal; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combination; Enoxaparin; Evidence-Based Medicine; Fibrinolytic Agents; Heparin; Humans; Hypoglycemic Agents; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Secondary Prevention; Stents; Thiophenes; Ticlopidine; Treatment Outcome | 2011 |
Dose of enoxaparin in review of rivaroxaban versus enoxaparin for prophylaxis of venous thromboembolism.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Female; Humans; Male; Morpholines; Thiophenes; Venous Thromboembolism | 2013 |
Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis.
Topics: Administration, Oral; Animals; Anticoagulants; Blood Coagulation; Carotid Artery Injuries; Coronary Occlusion; Coronary Thrombosis; Disease Models, Animal; Electrolytes; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Injections, Intravenous; Male; Morpholines; Partial Thromboplastin Time; Prothrombin Time; Rats; Rats, Sprague-Dawley; Rivaroxaban; Thiophenes | 2011 |
Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Clinical Trials, Phase III as Topic; Costs and Cost Analysis; Enoxaparin; Health Services; Humans; Morpholines; Rivaroxaban; Thiophenes; United States; Venous Thromboembolism | 2011 |
The effect of a new direct Factor Xa inhibitor on human osteoblasts: an in-vitro study comparing the effect of rivaroxaban with enoxaparin.
Topics: Aged; Alkaline Phosphatase; Anticoagulants; Bone Morphogenetic Protein 2; Cell Survival; Cells, Cultured; Core Binding Factor Alpha 1 Subunit; Enoxaparin; Factor Xa Inhibitors; Female; Gene Expression; Humans; Morpholines; Osteoblasts; Osteocalcin; Rivaroxaban; RNA, Messenger; Thiophenes | 2011 |
Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Enoxaparin; Humans; Middle Aged; Models, Economic; Morpholines; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; United States; Venous Thromboembolism | 2012 |
Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Decision Trees; Drug Costs; Elective Surgical Procedures; Enoxaparin; Female; Humans; Male; Markov Chains; Models, Economic; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; State Medicine; Thiophenes; United Kingdom; Venous Thromboembolism | 2012 |
Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Decision Making; Enoxaparin; Guidelines as Topic; Health Care Costs; Humans; Ireland; Models, Economic; Morpholines; Pyridines; Quality-Adjusted Life Years; Rivaroxaban; Technology Assessment, Biomedical; Thiophenes; Time Factors; Venous Thromboembolism | 2012 |
A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cost-Benefit Analysis; Databases, Factual; Decision Trees; Enoxaparin; Germany; Humans; Morpholines; Multicenter Studies as Topic; National Health Programs; Postoperative Complications; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme.
Topics: Anticoagulants; Arthroplasty, Replacement, Ankle; Arthroplasty, Replacement, Knee; Clinical Trials, Phase III as Topic; Enoxaparin; Hemarthrosis; Hemorrhage; Humans; Morpholines; Postoperative Complications; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2012 |
Extensive venous thrombosis in a healthy young man with a short inferior vena cava syndrome treated successfully with rivaroxaban.
Topics: Adult; Anticoagulants; Edema; Enoxaparin; Humans; Iliac Vein; Incidental Findings; Male; Morpholines; Rivaroxaban; Thiophenes; Tomography, X-Ray Computed; Travel; Vena Cava, Inferior; Venous Thrombosis; Warfarin; Young Adult | 2012 |
Abciximab for distal thromboaspiration catheter-related embolization in ST-segment elevated myocardial infarction.
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Aspirin; Combined Modality Therapy; Coronary Angiography; Coronary Thrombosis; Coronary Vessels; Electrocardiography; Embolism; Enoxaparin; Female; Humans; Immunoglobulin Fab Fragments; Infusions, Parenteral; Injections, Intra-Arterial; Middle Aged; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Stents; Suction; Thiophenes; Thrombectomy | 2012 |
[Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Budgets; Cost Control; Dabigatran; Enoxaparin; Female; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Humans; Morpholines; Polysaccharides; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Spain; State Medicine; Thiophenes; Venous Thromboembolism | 2012 |
Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Chemoprevention; Elective Surgical Procedures; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Osteoarthritis, Hip; Osteoarthritis, Knee; Outcome and Process Assessment, Health Care; Postoperative Complications; Rivaroxaban; Thiophenes; United Kingdom; Venous Thromboembolism; Wound Healing | 2013 |
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa.
Topics: Animals; Anticoagulants; Antidotes; Benzamides; Dose-Response Relationship, Drug; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Fondaparinux; Hemorrhage; Hemostasis; Male; Mice; Mice, Inbred C57BL; Morpholines; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Rabbits; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Rivaroxaban; Thiophenes | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Thiophenes; Venous Thromboembolism | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Thiophenes; Venous Thromboembolism | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Thiophenes; Venous Thromboembolism | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Thiophenes; Venous Thromboembolism | 2013 |
[Comparison of effects of two anticoagulants on hidden blood loss after total hip arthroplasty].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Volume; Enoxaparin; Female; Femur Head Necrosis; Humans; Injections, Subcutaneous; Male; Middle Aged; Morpholines; Postoperative Complications; Postoperative Hemorrhage; Retrospective Studies; Rivaroxaban; Thiophenes; Young Adult | 2013 |
Investigation of the effects of Enoxaparin, Fondaparinux, and Rivaroxaban used in thromboembolism prophylaxis on fracture healing in rats.
Topics: Animals; Enoxaparin; Femoral Fractures; Fibrinolytic Agents; Fondaparinux; Fracture Healing; Male; Morpholines; Polysaccharides; Rats; Rats, Sprague-Dawley; Rivaroxaban; Thiophenes; Thromboembolism; Tomography, X-Ray Computed | 2013 |
[Thromboprophylaxis in medical patients: Which modifications with the new oral anticoagulants?].
Topics: Administration, Oral; Anticoagulants; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism | 2013 |
Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.
Topics: Anticoagulants; Cost-Benefit Analysis; Drug Therapy, Combination; Enoxaparin; Humans; Markov Chains; Middle Aged; Morpholines; Quality-Adjusted Life Years; Rivaroxaban; Thiophenes; United States; Venous Thrombosis; Vitamin K | 2014 |
Investigation of the antiangiogenic behaviors of rivaroxaban and low molecular weight heparins.
Topics: Angiogenesis Inhibitors; Animals; Anticoagulants; Chick Embryo; Chorioallantoic Membrane; Enoxaparin; Heparin, Low-Molecular-Weight; Morpholines; Neovascularization, Physiologic; Rivaroxaban; Thiophenes; Tinzaparin | 2014 |
[Comparison of rivaroxaban and enoxaparin on blood loss after total knee arthroplasty].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Volume; Enoxaparin; Female; Humans; Male; Middle Aged; Morpholines; Osteoarthritis, Knee; Postoperative Complications; Retrospective Studies; Risk Factors; Rivaroxaban; Thiophenes; Treatment Outcome | 2014 |
Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrhage; Humans; Morpholines; Patient Selection; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Time Factors; Treatment Outcome; Venous Thromboembolism | 2014 |
Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Prospective Studies; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2014 |
Effects of enoxaparin and rivaroxaban on tissue survival in skin degloving injury: an experimental study.
Topics: Animals; Disease Models, Animal; Enoxaparin; Fibrinolytic Agents; Inflammation; Male; Morpholines; Necrosis; Rats; Rats, Sprague-Dawley; Rivaroxaban; Skin; Soft Tissue Injuries; Thiophenes; Tissue Survival; Trauma Severity Indices; Treatment Outcome | 2014 |
Thrombotic complications in heart failure: an underappreciated challenge.
Topics: Enoxaparin; Female; Heart Failure; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2014 |
Oral anticoagulation with rivaroxaban during pregnancy: a case report.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Drug Substitution; Enoxaparin; Female; Humans; Infant, Newborn; Live Birth; Male; Morpholines; Pregnancy; Pregnancy Complications, Cardiovascular; Recurrence; Risk Factors; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism; Young Adult | 2014 |
Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program.
Topics: Adolescent; Adult; Aged; Anticoagulants; Enoxaparin; Female; Humans; Length of Stay; Male; Middle Aged; Morpholines; Pulmonary Embolism; Rivaroxaban; Thiophenes; United States; Venous Thrombosis; Vitamin K; Young Adult | 2014 |
Results of rotational thromboelastometry, coagulation activation markers and thrombin generation assays in orthopedic patients during thromboprophylaxis with rivaroxaban and enoxaparin: a prospective cohort study.
Topics: Aged; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Cohort Studies; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Orthopedic Procedures; Prospective Studies; Rivaroxaban; Thiophenes; Thrombelastography; Thrombin; Venous Thromboembolism | 2015 |
The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Enoxaparin; Female; Gastrointestinal Hemorrhage; Heparin; Humans; Ischemic Attack, Transient; Longitudinal Studies; Male; Middle Aged; Morpholines; Patient Readmission; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Venous Thrombosis; Warfarin; Withholding Treatment | 2015 |
Severe and persistent heparin-induced thrombocytopenia despite fondaparinux treatment.
Topics: Aged, 80 and over; Antibodies; Anticoagulants; Blood Platelets; Dalteparin; Female; Fondaparinux; Hip Fractures; Hirudins; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Morpholines; Peptide Fragments; Platelet Count; Polysaccharides; Recombinant Proteins; Rivaroxaban; Thiophenes; Thrombocytopenia; Venous Thrombosis | 2015 |
Investigation of possible prophylactic, renoprotective, and cardioprotective effects of thromboprophylactic drugs against ischemia-reperfusion injury.
Topics: Animals; Anticoagulants; Aryldialkylphosphatase; Aspirin; Cardiotonic Agents; Clopidogrel; Dipeptidases; Drug Evaluation, Preclinical; Enoxaparin; Femoral Artery; Heparin, Low-Molecular-Weight; Hindlimb; Kidney; Male; Malondialdehyde; Morpholines; Myocardium; Nitric Oxide; Oxidative Stress; Rats, Sprague-Dawley; Reperfusion Injury; Rivaroxaban; Thiophenes; Ticlopidine | 2015 |
Letter to the Editor "Gender related aspects of bleeding with rivaroxaban in venous thromboembolism - Potential for pitfalls": A comment to "Impact of gender on safety and efficacy of rivaroxaban in adolescents & young adults with venous thromboembolism"
Topics: Adult; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes; Thrombosis; Venous Thromboembolism | 2016 |